How do you manage skin in Sscl? -RNA pol III + high risk for skin progression. -Limited+ low risk + stable Sscl no need for immunesuppresors. -Look for EF in pts with generalized morphea. -Ttnt of skin depending on other organ involvements. -If no Raynaud’s/hands spared think of… https://t.co/HBjO5eQfjT https://t.co/oS1ZmkanGA

de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX

Sarilumab is better than #MTX in #PMR Reminder #RCT of #MTX in #PMR was a NEGATIVE #trial #1697 60 % #sarilumab in #RWE could d/c #Prednisone after failure of initial #pred #Rx >1yr pred prior vs 40% MTX Comparative effectiveness sari v MTX #1700 #ACR24 @ACRheum @RheumNow https://t.co/4YXIBz0OK7

A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py) RZV is effective in preventing HZ & PhN @Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl

Bolhuis et al. PMR MODE study. MTX 25mg/week in recently diagnosed PMR. 52 weeks. 56 patients. Nada, zip, no effect. GC free remission 67% vs 68%. No difference in any secondary outcome. @RheumNow #ACR24 Abstr#1697 #ACRbest https://t.co/Mb909u1zFT https://t.co/dShyBF4WST

RA-ILD: 💡Lifetime prevalence seems low but ~40% can have subclincal. 💡Screen early in symptomatic pts. 💡RA disease control decreases ILD progression and mortality. 💡RA-ILD UIP pattern seems to respond to immunosuppression. #ACR24 @RheumNow https://t.co/q3iACMeYVU

When you stop 🛑 #TCZ #tocilizumab at 6 months of #Rx in #PMR RELAPSES are V high DON’T stop #Toci in PMR too Early Rapid and frequent flares #ACR24 @RheumNow @ACRheum #1698 https://t.co/IX5EJOcIY5

A#1692 Single cell RNA-seq identifies double-negative-2 (DN2) B-cell population ass w progressive SSc-ILD IgD- CD27- cluster is highest risk CD21 low B cells are distinct subset associated with sclerosis, pHTN DN2 B cells as potential biomarkers for SSc-ILD @RheumNow #ACR24 https://t.co/IbnOGS8C3t

Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3

This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx